Literature DB >> 25249201

NICE, social values, and balancing objectivity and equity.

Suzanne R Hill1, Leslie G Olson.   

Abstract

Mesh：

Year:  2014        PMID： 25249201     DOI： 10.1007/s40273-014-0220-4

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  12 in total

1.  Two ideas to increase innovation and reduce pharmaceutical costs and prices.

Authors:  Arjun Jayadev; Joseph Stiglitz
Journal:  Health Aff (Millwood)       Date:  2008-12-16       Impact factor: 6.301

2.  Value-based differential pricing: efficient prices for drugs in a global context.

Authors:  Patricia Danzon; Adrian Towse; Jorge Mestre-Ferrandiz
Journal:  Health Econ       Date:  2013-12-11       Impact factor: 3.046

3.  Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture.

Authors:  Tito Fojo; Sham Mailankody; Andrew Lo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-12       Impact factor: 6.223

4.  Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.

Authors:  Cornelia Henschke; Leonie Sundmacher; Reinhard Busse
Journal:  Health Policy       Date:  2013-01-20       Impact factor: 2.980

5.  Some inconsistencies in NICE's consideration of social values.

Authors:  Mike Paulden; James F O'Mahony; Anthony J Culyer; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2014-11       Impact factor: 4.981

6.  Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.

Authors:  Hong Anh T Tu; Shelley L Deeks; Shaun K Morris; Lisa Strifler; Natasha Crowcroft; Frances B Jamieson; Jeffrey C Kwong; Peter C Coyte; Murray Krahn; Beate Sander
Journal:  Vaccine       Date:  2014-08-12       Impact factor: 3.641

7.  Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.

Authors:  Cyrus Mehta; Helmut Schäfer; Hanna Daniel; Sebastian Irle
Journal:  Stat Med       Date:  2014-07-30       Impact factor: 2.373

8.  Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.

Authors:  Peter J Neumann; Joshua T Cohen; Milton C Weinstein
Journal:  N Engl J Med       Date:  2014-08-28       Impact factor: 91.245

9.  What drives health-care spending priorities? An international survey of health-care professionals.

Authors:  Glenn Salkeld; David Henry; Suzanne Hill; Danielle Lang; Nick Freemantle; Jefferson D'Assunção
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

10.  Oncology drug health technology assessment recommendations: Canadian versus UK experiences.

Authors:  Isabelle Chabot; Angela Rocchi
Journal:  Clinicoecon Outcomes Res       Date:  2014-07-16
View more
  1 in total

1.  Objectivity and equity: clarity required. A response to Hill and Olson.

Authors:  Mike Paulden; James F O'Mahony; Anthony J Culyer; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2014-12       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.